explore -WSS

explore

author：leisure time 2025-09-27 09:40:08 - browse：6

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Questions and answers about ramping up H5N1 bird flu vaccine

WSS

H5N1 virus can be tracked in retail milk, scientists say

Eyeing GLP

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Liquid biopsy for lung cancer is launched by Delfi

H5N1 virus can be tracked in retail milk, scientists say

Eyeing GLP

explore

explore

Wikipedia

How one medical school became remarkably diverse

Biogen joins immunology wave with $1.15 billion acquisition of HI

Medicare proposal to cover medical devices draws a mixed reaction

3 questions for the future of Biden's cancer moonshot

Cancer drug shortages should be causing more outrage

Fentanyl is making it harder to start addiction treatment

Continuity nursing helped my family in our darkest PICU moments

Listen: A conversation with researcher Kevin Esvelt on biosecurity

ChatGPT in medicine: STAT answers readers' burning questions

Chan Zuckerberg Biohub Chicago to focus on inflammation

explore

Stroke deaths set to near 10 million globally by 2050

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Why age limits for politicians are a terrible idea

For longer

Physician executives need more than on

Colorectal cancer study finds potential in overlooked immune cell

entertainment

hotspot

knowledge

explore